Jane Doe

And so Novo Nordisk had set this expectation that this potential new drug could help people lose 25% of their body weight, which would be a higher bar than what ZepBound has shown for the most part.

And so Novo Nordisk had set this expectation that this potential new drug could help people lose 25% of their body weight, which would be a higher bar than what ZepBound has shown for the most part.

It was basically about 22%. But I think the stakes are so high in this industry and among investors that even this small shortfall was a huge disappointment. In a single day in December, Novo Nordisk's share price dropped 20%. And it cut $100 billion worth off their market cap. Wow. And you just don't see that very often for a large pharmaceutical company.

It was basically about 22%. But I think the stakes are so high in this industry and among investors that even this small shortfall was a huge disappointment. In a single day in December, Novo Nordisk's share price dropped 20%. And it cut $100 billion worth off their market cap. Wow. And you just don't see that very often for a large pharmaceutical company.

It was basically about 22%. But I think the stakes are so high in this industry and among investors that even this small shortfall was a huge disappointment. In a single day in December, Novo Nordisk's share price dropped 20%. And it cut $100 billion worth off their market cap. Wow. And you just don't see that very often for a large pharmaceutical company.

Well, one thing I've learned is that investors get used to things pretty quickly and they want the next thing.

Well, one thing I've learned is that investors get used to things pretty quickly and they want the next thing.

Well, one thing I've learned is that investors get used to things pretty quickly and they want the next thing.

By pharmaceutical industry standards, that's a pretty fast ramp. Zepbound came out at the end of 2023, and in just a year, it was able to take the top spot from Wegovy. And so at some point in the last several weeks, the chair of the Novo Nordisk Foundation expressed his concerns to the board of directors of the drug company.

By pharmaceutical industry standards, that's a pretty fast ramp. Zepbound came out at the end of 2023, and in just a year, it was able to take the top spot from Wegovy. And so at some point in the last several weeks, the chair of the Novo Nordisk Foundation expressed his concerns to the board of directors of the drug company.

By pharmaceutical industry standards, that's a pretty fast ramp. Zepbound came out at the end of 2023, and in just a year, it was able to take the top spot from Wegovy. And so at some point in the last several weeks, the chair of the Novo Nordisk Foundation expressed his concerns to the board of directors of the drug company.

And that began a discussion that they should speed up their timelines for a CEO transition.

And that began a discussion that they should speed up their timelines for a CEO transition.

And that began a discussion that they should speed up their timelines for a CEO transition.

I mean, he has said in interviews that he was surprised, you know, that he's proud of his time there, what he did.

I mean, he has said in interviews that he was surprised, you know, that he's proud of his time there, what he did.

I mean, he has said in interviews that he was surprised, you know, that he's proud of his time there, what he did.

Joining the Novo Nordisk Drugmaker Board of Directors will be the old Lars. Lars Sorensen. The former CEO and the outgoing CEO are both named Lars. So it's a case of, you know, out with the new Lars, in with the old Lars. Yeah.

Joining the Novo Nordisk Drugmaker Board of Directors will be the old Lars. Lars Sorensen. The former CEO and the outgoing CEO are both named Lars. So it's a case of, you know, out with the new Lars, in with the old Lars. Yeah.

Joining the Novo Nordisk Drugmaker Board of Directors will be the old Lars. Lars Sorensen. The former CEO and the outgoing CEO are both named Lars. So it's a case of, you know, out with the new Lars, in with the old Lars. Yeah.